A hazard ratio of 0.62, with less toxicity than the comparator.

In second-line metastatic disease, standard of care delivers a median progression-free survival of 4.1 months and an overall response rate of 26%. No new mechanism has been approved in this setting since 2015, and roughly 118,000 patients a year across the United States, European Union and Japan cycle through it.^[1]

HLX-207 is a first-in-class oral allosteric inhibitor targeting a resistance node that the existing agents do not touch. In ASCEND-2 it produced a hazard ratio of 0.62 for progression or death, against an active comparator, in a randomised double-blind trial of 1,215 patients.^[2]

The asset is wholly owned. There is no partner, no milestone stack and no royalty burden ahead of a commercial launch.^[1]

Helix Therapeutics Inc. is a clinical-stage biopharmaceutical company incorporated in Delaware — founded in 2018 around translational work on a resistance node that reliably reactivates signalling after first-line therapy fails.^[1]

The company holds worldwide rights to HLX-207 and, following the 2024 acquisition of Ridgeline Bio, to HLX-330, a monoclonal antibody against the same pathway being developed for combination use.^[1]

On January 22, 2026, Helix reported topline results from ASCEND-2, a randomised, double-blind Phase 2b study of HLX-207 versus active comparator in 1,215 patients with second-line metastatic disease across 148 sites in 19 countries.^[2]

The study met its primary endpoint. Median progression-free survival was 9.4 months on HLX-207 versus 4.1 months on comparator, a hazard ratio of 0.62 (95% CI 0.51–0.75, p < 0.001). Overall response rate was 45.9% versus 26.2%. Grade 3 or higher treatment-related adverse events occurred in 18.4% of the HLX-207 arm versus 31.7% of the comparator arm.^[2]

A better hazard ratio with a lower toxicity burden is the combination that changes prescribing behaviour — and it is the combination regulators grant Breakthrough Therapy designation for.^[2][5]

Most agents in this pathway are orthosteric: they occupy the active site and compete directly with the natural substrate. That competition is what drives both the escape mutations that produce resistance and the off-target toxicity that limits dosing.^[4]

HLX-207 binds an allosteric pocket instead, locking the target in an inactive conformation. Substrate concentration is irrelevant to potency, and the known resistance mutations do not sit in the binding pocket.

Translational work confirmed that selectivity for the target over the nearest three paralogues exceeds 400-fold, which is the structural reason the Grade 3+ adverse event rate in ASCEND-2 came in below the comparator rather than above it. The tolerability is a property of the binding site, not of careful dose management.^[4]

“The ASCEND-2 results are definitive. They confirm that allosteric inhibition of this node delivers a clinically meaningful survival benefit with a tolerability profile better than existing standard of care. The potential to move this into first-line combination, alongside our wholly owned antibody, represents a compelling pathway for value creation.”

After first-line therapy, tumour cells reactivate downstream signalling through a compensatory node that is not itself the original driver. The node is druggable but has resisted orthosteric approaches because its active site is shallow and highly conserved across paralogues.^[4]

HLX-207 binds a cryptic pocket 14 Å from the active site, identified through fragment screening and confirmed by co-crystal structure at 1.9 Å resolution. Binding stabilises an inactive conformation and blocks the conformational change required for catalysis, without ever contacting the substrate-binding surface.^[4]

Between 2021 and 2023 the asset was evaluated in an open-label Phase 1/1b program in 96 patients, establishing dose, exposure and early signals of activity. Those data are early-phase, single-arm and uncontrolled, and are not comparable to the randomised ASCEND-2 results.^[3]

The HELIOS-1 program comprised 96 patients across dose escalation and three expansion cohorts, with notable results including:^[3]

The expansion cohorts enrolled heavily pretreated patients with a median of three prior lines of therapy, a population in which the historical response rate to available agents is in the range of 8–12%. Duration of response of 7.8 months in that setting was the basis for the randomised Phase 2b design and for the choice of progression-free survival as the primary endpoint.^[3]

These results are from an open-label, single-arm, early-phase study and should not be relied upon as evidence of efficacy, nor treated as comparable to randomised controlled data. Early-phase response rates in small, selected populations frequently fail to replicate in randomised settings. Cross-trial comparisons to historical response rates are not valid comparisons. Helix Therapeutics Inc. is a fictional issuer and every figure on this page is illustrative; no product referenced here exists or has been approved by any regulatory authority for any use.

Preclinical and translational findings are exploratory in nature and frequently do not translate to clinical benefit in humans. They are presented to describe the scientific rationale for the program and should not be relied upon as evidence of safety or efficacy.^[4]

Phase 3 follows the End-of-Phase-2 meeting held in May 2026, at which the agency aligned on overall survival as the primary endpoint, on the second-line population, and on the use of ASCEND-2 progression-free survival data as supportive. First patient in is guided for the fourth quarter, with a parallel Phase 1b combination study of HLX-207 and HLX-330 opening in the same period.^[5]

Second-line metastatic disease is a large, poorly served and commercially concentrated setting: three products hold more than 80% of prescriptions, all of them intravenous, all of them approved before 2016.^[1]

Helix's strategy is to establish HLX-207 as the oral standard of care in second line, then move the wholly owned combination forward into first line — retaining full economics through launch rather than partnering the asset away at the point of maximum leverage.^[1]

The program benefits from Breakthrough Therapy designation, which brings intensive agency guidance and eligibility for rolling review. The combination of a differentiated mechanism, a favourable tolerability profile and an undisrupted commercial setting positions HLX-207 as an asset with significant clinical and strategic potential.^[5]

HLX-330 is a humanised monoclonal antibody blocking the same pathway at the receptor. It was acquired with Ridgeline Bio in 2024 for $62M upfront, and is being developed for combination use with HLX-207 rather than as a standalone agent.^[1]

*Ridgeline Bio Inc., asset purchase agreement and audited statements (2024). Patent term is illustrative and excludes any potential extension.^[6]

The combination rationale is straightforward: allosteric inhibition suppresses the resistance node intracellularly while the antibody blocks upstream receptor engagement. In xenograft models the pair produced deeper and more durable regression than either agent alone.^[4]

Combination testing is what carries the mechanism into first line, where the addressable population is roughly three times larger and where duration of therapy is substantially longer — which is why the tolerability profile from ASCEND-2 matters more than the response rate does.^[1]

Helix Therapeutics Inc. acknowledges that every number on this page was produced by patients and families who accepted uncertainty at the hardest point in their lives, and by investigators and site staff across 19 countries. The company recognises an obligation to them that runs past the readout.^[1]

• Publish full trial results, including negative and secondary endpoints
• Register every study and post results within regulatory timelines
• Offer post-trial access to participants who continue to benefit
• Design enrolment for demographic representativeness, and report it
• Maintain an expanded access policy and publish the criteria

The approach is grounded in the principles of informed consent, data transparency and equitable access — on the belief that a medicine is only worth developing if the people who made it possible can see what it produced.^[1]